Pros and cons of the liposome platform in cancer drug targeting.
about
Targeted Doxorubicin Delivery to Brain Tumors via Minicells: Proof of Principle Using Dogs with Spontaneously Occurring Tumors as a Model.Liposomes as nanomedical devicesControllable microfluidic synthesis of multiphase drug-carrying lipospheres for site-targeted therapyGold nanorod-mediated photothermolysis induces apoptosis of macrophages via damage of mitochondria.Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model.Preparation of RGD-modified long circulating liposome loading matrine, and its in vitro anti-cancer effects.Lipodox® (generic doxorubicin hydrochloride liposome injection): in vivo efficacy and bioequivalence versus Caelyx® (doxorubicin hydrochloride liposome injection) in human mammary carcinoma (MX-1) xenograft and syngeneic fibrosarcoma (WEHI 164) mousRecent advancements in cytotoxic T lymphocyte generation methods using carbohydrate-coated liposomesNovel nanomaterials for clinical neuroscience.Doxazolidine induction of apoptosis by a topoisomerase II independent mechanism.Liposomal nanostructures for photosensitizer delivery.Long-circulating 15 nm micelles based on amphiphilic 3-helix peptide-PEG conjugatesNANOMATERIALS FOR PROTEIN MEDIATED THERAPY AND DELIVERY.Targeted nanogels: a versatile platform for drug delivery to tumorsChemoradionuclide therapy with 186Re-labeled liposomal doxorubicin in combination with radiofrequency ablation for effective treatment of head and neck cancer in a nude rat tumor xenograft model.Polymer genomics: an insight into pharmacology and toxicology of nanomedicinesTargeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance.Synthesis and evaluation of a novel ligand for folate-mediated targeting liposomesProgrammed drug delivery: nanosystems for tumor targeting.Targeted drug delivery utilizing protein-like molecular architecture.Polydopamine-based surface modification for the development of peritumorally activatable nanoparticlesNanovehicular intracellular delivery systems.Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation.Imaging characteristics of zinc sulfide shell, cadmium telluride core quantum dots.Silicon micro- and nanofabrication for medicine[(186)Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model.Fliposomes: pH-Sensitive Liposomes Containing a trans-2-morpholinocyclohexanol-Based Lipid That Performs a Conformational Flip and Triggers an Instant Cargo Release in Acidic Medium.Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery.The nasal delivery of nanoencapsulated statins - an approach for brain deliveryMetabolism and excretion of novel pulmonary-targeting docetaxel liposome in rabbits.Recent advances in tumor vasculature targeting using liposomal drug delivery systems.Nanomaterial standards for efficacy and toxicity assessment.Polymeric micelles as a new drug carrier system and their required considerations for clinical trials.Chitin and chitosan as multipurpose natural polymers for groundwater arsenic removal and AS2O3 delivery in tumor therapy.Liposomes targeting tumour stromal cells.Multimodality Imaging of Integrin α(v)β(3) Expression.Optimizing Druggability through Liposomal Formulations: New Approaches to an Old Concept.Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system.Gemcitabine-loaded liposomes: rationale, potentialities and future perspectives.Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery.
P2860
Q27316967-23825C4E-B167-4572-91B9-E2B03150E896Q28088315-5299F844-7A43-4F48-8C5B-D137BBF10914Q30480712-3145A3EA-23E6-4BCA-9527-C3952F69C3BCQ33424019-FA02D171-81E5-45D3-983E-D71BD608F58FQ33564844-290127F4-C5C1-4360-B2EE-2F335B980FFBQ33623605-9E95D598-57F3-413F-83F3-363D13B2EC7AQ33771516-BD05E2B5-E62C-4489-AE49-B7357E66814DQ33959996-4DEB41CA-7F66-4D82-9A1D-E839734634EAQ34009532-3AC2711D-295A-48CE-B7AF-19434236994AQ34056786-F2C3F32E-C96A-4438-B2E9-85686D1BA02FQ34068206-A04EB38B-4928-4D24-ACFF-30C15B4BC818Q34251745-23550571-A3C1-4991-913D-76C840F09068Q34534023-685FA8BF-C746-4C23-83A0-80903B4848F8Q35038164-6BFD3D59-DFBF-498A-BE5B-E31956D60FBBQ35560987-614475C4-C520-4B91-877D-271A8815BCFAQ35754353-C6D52FD8-B387-49F3-BDF9-019963B051B8Q36680180-6F36D6D4-693D-4185-8337-B12D6A7F639CQ36713632-AD9B9A27-523B-417F-AB18-99994AACF9B4Q36810261-6B91A380-7C7B-4DFA-BEDD-F7CD13D1EE58Q36846806-E77C43DD-B938-49FB-BD60-1DBE415415A8Q36979875-6221F5D5-432E-459A-9225-8C9359A6951AQ37058812-3C48E5DD-4759-41B2-BBAE-AEB784DD0C43Q37059896-EA2327CD-8F39-4A10-9D33-A4A121A95172Q37167336-2F84A774-960A-4B5F-A679-CA4FEFC8467EQ37184228-30644489-E5C1-4711-B1EA-6FD344879C5CQ37226674-552C0DF5-5714-4206-A188-3A630F1CB047Q37378137-84444993-C836-4D9C-8226-23F6C7B64A23Q37444094-A84EC5F9-72DB-4894-8134-E64700FEF228Q37496394-EFF06DA5-3385-4712-9227-1B7B15935CBBQ37559578-39DFC453-4BCB-461A-93C0-BE93CB64E0EAQ37603355-9E8AD65C-726E-4F59-B73A-9CECE61F75D2Q37668451-5A2BDCF6-7A6F-4CC3-924D-4C17F32D883DQ37679942-8E0E4FBC-18B5-4BCC-AC62-EDB650CB0586Q37766096-A41BE956-EF18-45BF-880E-0D70E4C422B2Q37799613-E5AA7364-8DB9-43F5-93EF-5C3E6F40CEEDQ37872610-181E835D-9E8A-465A-8F19-E2CF68A0E80AQ37999793-10A9B7D5-1A87-4F3E-9426-6233558D0D7CQ38038897-666191F2-9802-401D-BD17-CAD377BA79CBQ38058785-AED0BF2F-A27D-4D41-B512-DDABFA0C42D1Q38067265-2AA9578D-2AA3-413C-AEFC-A35074076AA1
P2860
Pros and cons of the liposome platform in cancer drug targeting.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Pros and cons of the liposome platform in cancer drug targeting.
@ast
Pros and cons of the liposome platform in cancer drug targeting.
@en
type
label
Pros and cons of the liposome platform in cancer drug targeting.
@ast
Pros and cons of the liposome platform in cancer drug targeting.
@en
prefLabel
Pros and cons of the liposome platform in cancer drug targeting.
@ast
Pros and cons of the liposome platform in cancer drug targeting.
@en
P2093
P1476
Pros and cons of the liposome platform in cancer drug targeting.
@en
P2093
Alberto A Gabizon
Hilary Shmeeda
Samuel Zalipsky
P304
P356
10.1080/08982100600848769
P577
2006-01-01T00:00:00Z